Skip to main content

Advertisement

SpringerLink
Log in

Clinical Impact of Tumor-infiltrating Lymphocytes for Survival in Curatively Resected Stage IV Colon Cancer with Isolated Liver or Lung Metastasis

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The most reliable prognostic factor to date is tumor, node, metastasis stage. However, prognostic significance of tumor-infiltrating lymphocytes (TILs) in curatively resected stage IV colon cancer with isolated liver or lung lesion has not been clarified. The aim of this study was to assess and compare the prognostic role of TILs in curatively resected stage IV colon cancers.

Methods

Immunohistochemistry was used to assess the densities of CD8+, CD45RO+, and FOXP3+ according to tumor sites (primary tumor, liver, and lung) from 79 stage IV colon cancers. These were evaluated for association with histopathologic features and patients’ overall survival (OS).

Results

Higher density of CD45RO+ at primary and metastatic sites was associated with better patient outcomes (P = 0.009 and 0.027, respectively). The estimated 3-year OS rates for high-density CD45RO+ at metastatic and primary sites was 82.6 and 62.4 %, respectively, compared to 60.8 and 27.1 % in low-density CD45RO+. In multivariate analysis, CD45RO+ at the colon primary site (P = 0.007; relative risk 0.108; 95 % confidence interval 0.021–0.546) was the strongest prognostic factor.

Conclusions

High density of CD45RO+ TILs showed independent prognostic significance for OS. This result may help to improve the prognostication of curatively resected stage IV colon cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.

    Article  PubMed  Google Scholar 

  2. South and West Cancer Intelligence Unit. Wessex colorectal audit: final report—5-year outcomes. Winchester: South and West Cancer Intelligence Unit; 2000.

  3. Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007;22:699–704.

    Article  PubMed  Google Scholar 

  4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.

    Article  PubMed  CAS  Google Scholar 

  5. Ohlsson B, Stenram U, Tranberg KG. Resection of colorectal liver metastases: 25-year experience. World J Surg. 1998;22:268–76.

    Article  PubMed  CAS  Google Scholar 

  6. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.

    Article  PubMed  CAS  Google Scholar 

  7. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105–12.

    PubMed  Google Scholar 

  8. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.

    Article  PubMed  Google Scholar 

  9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.

    Article  PubMed  CAS  Google Scholar 

  10. Lee WS, Yun HR, Yun SH, et al. Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol. 2008;23:e367–72.

    Article  PubMed  Google Scholar 

  11. Adam R, de Haas RJ, Wicherts DA, et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg. 2011;253:349–59.

    Article  PubMed  Google Scholar 

  12. Aoki T, Umekita N, Tanaka S, Noda K, Warabi M, Kitamura M. Prognostic value of concomitant resection of extrahepatic disease in patients with liver metastases of colorectal origin. Surgery. 2008;143:706–14.

    Article  PubMed  Google Scholar 

  13. Carpizo DR, Are C, Jarnagin W, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009;16:2138–46.

    Article  PubMed  Google Scholar 

  14. de Haas RJ, Wicherts DA, Adam R. Resection of colorectal liver metastases with extrahepatic disease. Dig Surg. 2008;25:461–6.

    Article  PubMed  Google Scholar 

  15. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.

    Article  PubMed  CAS  Google Scholar 

  16. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102:18538–43.

    Article  PubMed  CAS  Google Scholar 

  17. Overwijk WW. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol. 2005;17:187–94.

    Article  PubMed  CAS  Google Scholar 

  18. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.

    Article  PubMed  Google Scholar 

  19. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986–92.

    Article  PubMed  Google Scholar 

  20. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  21. Chai SM, Zeps N, Shearwood AM, et al. Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:1017–25.

    Article  PubMed  CAS  Google Scholar 

  22. Michel S, Benner A, Tariverdian M, et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer. 2008;99:1867–73.

    Article  PubMed  CAS  Google Scholar 

  23. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. Cancer. 2010;116:5188–99.

    Article  PubMed  Google Scholar 

  24. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+ Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007;79:310–6.

    Article  PubMed  CAS  Google Scholar 

  25. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006;4:52.

    Article  PubMed  Google Scholar 

  26. Katz SC, Pillarisetty V, Bamboat ZM, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:2524–30.

    Article  PubMed  Google Scholar 

  27. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.

    Article  PubMed  CAS  Google Scholar 

  28. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586–93.

    Article  PubMed  Google Scholar 

  29. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.

    Article  PubMed  CAS  Google Scholar 

  30. Chew A, Salama P, Robbshaw A, et al. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer. PLoS One. 2011;6:e22047.

    Article  PubMed  CAS  Google Scholar 

  31. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol. 2009;9:153–61.

    Article  PubMed  CAS  Google Scholar 

  32. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704–11.

    Article  PubMed  CAS  Google Scholar 

  33. Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670–7.

    Article  PubMed  CAS  Google Scholar 

  34. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.

    Article  PubMed  CAS  Google Scholar 

  35. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.

    Article  PubMed  CAS  Google Scholar 

  36. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137–48.

    Article  PubMed  CAS  Google Scholar 

  37. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010;22:215–22.

    Article  PubMed  CAS  Google Scholar 

  38. Camus M, Tosolini M, Mlecnik B, et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009;69:2685–93.

    Article  PubMed  CAS  Google Scholar 

  39. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68:2561–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

All of the listed authors claim no conflict of interest and financial disclosure.

Author information

Authors and Affiliations

  1. Department of Surgery, Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea

    Won-Suk Lee MD, PhD & Jeong-Heum Baek MD, PhD

  2. Department of Pathology, Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea

    Myunghee Kang MD & Seung Yeon Ha MD, PhD

  3. Department of Thoracic Surgery, Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea

    Jae-Ik Lee MD, PhD

Authors
  1. Won-Suk Lee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myunghee Kang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeong-Heum Baek MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae-Ik Lee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seung Yeon Ha MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seung Yeon Ha MD, PhD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 1728 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, WS., Kang, M., Baek, JH. et al. Clinical Impact of Tumor-infiltrating Lymphocytes for Survival in Curatively Resected Stage IV Colon Cancer with Isolated Liver or Lung Metastasis. Ann Surg Oncol 20, 697–702 (2013). https://doi.org/10.1245/s10434-012-2752-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2752-1

Keywords

Search

Navigation